Aggregate national experience with the wearable cardioverter-defibrillator: event rates, compliance, and survival. - Wikidata - awgldk - TriplyDB

Aggregate national experience with the wearable cardioverter-defibrillator: event rates, compliance, and survival.

Aggregate national experience with the wearable cardioverter-defibrillator: event rates, compliance, and survival.

http://www.wikidata.org/entity/Q34233026

about

Value of The Wearable Cardioverter Defibrillator (WCD) as a Bridging-Therapy before Implantation of a Cardioverter Defibrillator (ICD)The Wearable Cardioverter/Defibrillator - Toy Or Tool?New horizon for infection prevention technology and implantable device 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator.Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function-value of the wearable cardioverter/defibrillator.Outpatient treatment with the wearable cardioverter defibrillator: clinical experience in two Dutch centres.Surgical and electrophysiological considerations in the management of a patient with a subcutaneous implantable cardioverter-defibrillator undergoing coronary artery bypass surgery.Sudden cardiac arrest in hemodialysis patients with wearable cardioverter defibrillator Wearable cardioverter defibrillator: Bridge or alternative to implantation?Wearable defibrillator use in heart failure (WIF): results of a prospective registry Usefulness of the wearable cardioverter defibrillator in patients in the early post-myocardial infarction phase with high risk of sudden cardiac death: A single-center European experience.Early risk of mortality after coronary artery revascularization in patients with left ventricular dysfunction and potential role of the wearable cardioverter defibrillator.Experience With the Wearable Cardioverter-Defibrillator in Patients at High Risk for Sudden Cardiac Death Wearable cardioverter defibrillator in stress cardiomyopathy and cardiac arrest.Wearable cardioverter defibrillator: a life vest till the life boat (ICD) arrives Application of ICD guidelines and indications in a community-based academic hospital: a case series-based discussion.Implantable cardioverter-defibrillator implementation in acute heart failure syndromes: unanswered questions.Indications for implantable cardioverter-defibrillator placement in ischemic cardiomyopathy and after myocardial infarction.Cardiovascular implantable electronic device leads in CKD and ESRD patients: review and recommendations for practice.Effectiveness of wearable defibrillators: systematic review and quality of evidence.Cardiac strangulation from epicardial pacemaker leads: diagnosis, treatment, and prevention.An appropriate shock of the wearable cardioverter-defibrillator in an outpatient setting.The use of wearable cardioverter-defibrillators in Europe: results of the European Heart Rhythm Association survey.Use of the Wearable Cardioverter Defibrillator in High-Risk Populations.The wearable cardioverter defibrillator as a bridge to implantable defibrillator post myocardial infarction: what do we know?Roles and indications for use of implantable defibrillator and resynchronization therapy in the prevention of sudden cardiac death in heart failure.The wearable cardioverter-defibrillator: current technology and evolving indications.Frequency and Implications of Ischemia Prior to Ventricular Tachyarrhythmia in Patients Treated With a Wearable Cardioverter Defibrillator Following Myocardial Infarction.National experience with long-term use of the wearable cardioverter defibrillator in patients with cardiomyopathy.[The Wearable Cardioverter-Defibrillator (WCD)].Ventricular fibrillation cardiac arrest due to 5-fluorouracil cardiotoxicity.Real world utilization and impact of the wearable cardioverter-defibrillator in a community setting.Venous Hemodialysis Catheters and Cardiac Implantable Electronic Devices: Avoiding a High-Risk Combination.[Pacemaker dependant and/or repetitive ICD therapies. How to solve the dilemma of lead extraction?].Protection from outpatient sudden cardiac death following ICD removal using a wearable cardioverter defibrillator.Pocket infections of cardiac implantable electronic devices treated by negative pressure wound therapy.Indications and use of the wearable cardiac defibrillator.Normalization of left ventricular ejection fraction after cardiac resynchronization therapy also normalizes survival.Wearable cardioverter defibrillators for the prevention of sudden cardiac arrest: a health technology assessment and patient focus group study.

P2860

Q28067809-EA822D50-5D29-4FB3-A943-DA7C9AE643B0 Q28077810-439D6F14-34E9-4172-86E4-A8ADA6732F39 Q28080257-52EAB7F4-FAED-4CBB-8562-B9164ADE9440 Q28087002-6D27ADB2-0E2D-4FEA-A88A-64ABE341078D Q33162850-89235500-8C33-4901-9C73-E73EF8D685A1 Q33164921-A5011DDF-7D29-4FC3-B965-BF106DF7519C Q33603090-976067DA-8EA4-425D-B371-1E98F2A8FE6B Q33644411-40AF4389-F657-4C6B-8C13-8B555C449E55 Q33667761-7DF00E93-DF3B-46B0-A245-B6F86166CB3D Q33854130-309BAF40-18B8-400D-AB3B-B280B91A35B4 Q34509631-14747C5E-EF75-4585-8BBB-29B553FA3B38 Q36146127-F7A42182-FA52-44BF-B71D-D903165B7E21 Q36913808-AAF27920-48B2-456D-AD61-0D0FE9CF0F45 Q37204531-3B4E2663-43A3-4023-8497-FC1AF832E14C Q37223588-B2D4DE96-7D6A-45B6-8BA2-8D184FEBDDD5 Q37624451-B5D1CC2D-3B66-42F3-97C7-47EA645F2633 Q37711369-D7072116-0F5A-4780-9177-24E957E0E4CE Q37855663-E4811CE7-5C45-4E12-8B93-98CBFB162981 Q37902558-60ED0F34-8D8A-412E-87FF-2365D2A7BBCD Q38034565-67A3BF8B-CD52-4D8A-BDC3-C50B4BAADF37 Q38217348-06076D7C-C240-485C-8C68-440AC61FC05F Q38258632-B8037A38-AEC2-4681-A43A-978DFD31E9D2 Q38551177-05C99B81-586B-42F8-80CD-5BEE46C0728C Q38722132-3CFA5DF1-C6C1-442D-B04E-A80D102A0B92 Q38869631-EBF2E1B1-A92F-43FC-8A71-A359EBC3001D Q38873501-A435656F-11E6-4A97-B1A6-526CC44DD324 Q38903885-8BAFC3F5-C21C-44A4-926F-482678ECC4CD Q38972235-BB67DAC4-B906-4E05-99C5-32E2715CB399 Q39657207-03E38E58-B96E-4331-B7FB-6A34C2263174 Q40535840-A98E2578-058D-4722-8045-1D1A6E7B45C8 Q41260532-09646F8C-55A8-44D6-BD38-1BEAE6AAEE18 Q42110118-2A389DE0-4611-4FC2-9CAB-33DC0329C44C Q42982081-1E833BB1-2BE9-443B-8BE6-A1C54B744C4F Q43663688-DE8A20F2-84D8-48C1-BE7E-7F5123EC5EBC Q43870913-93B5451C-6A92-4D5D-9A03-890A4AF42B35 Q44000261-0A6B7C1D-F750-4729-8B9B-2CA62E1849A2 Q44971802-7F1EB005-0454-48AB-93B2-DE0618B14A53 Q45052440-199AC390-98DD-487B-8456-CA69E3658EF2 Q45788170-0B064A9E-90F2-44AA-929E-D1845079CD19 Q46329648-E5E6E90F-F8D8-420E-B0E2-6ED98BAE9A75

P2860

Aggregate national experience with the wearable cardioverter-defibrillator: event rates, compliance, and survival.

http://www.wikidata.org/entity/Q34233026

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Aggregate national experience ...... tes, compliance, and survival.

@ast

Aggregate national experience ...... tes, compliance, and survival.

@en

Aggregate national experience ...... tes, compliance, and survival.

@nl

type

label

Aggregate national experience ...... tes, compliance, and survival.

@ast

Aggregate national experience ...... tes, compliance, and survival.

@en

Aggregate national experience ...... tes, compliance, and survival.

@nl

prefLabel

Aggregate national experience ...... tes, compliance, and survival.

@ast

Aggregate national experience ...... tes, compliance, and survival.

@en

Aggregate national experience ...... tes, compliance, and survival.

@nl

P1433

Q34233026-D8B21E54-9AF0-41CF-A41D-113A944BD995

P1476

Q34233026-8EFFB1F3-7B75-4010-8787-4E5BF99B813A

P2093

Q34233026-07808D5F-6651-4238-B795-A2708B538420

Q34233026-0C217A7D-1BB9-4627-B865-634FA77A33C7

Q34233026-766E058F-57D3-4729-9D0A-6E0209E86FD6

Q34233026-AB5613BC-1983-4CCF-839B-79E8BD71E9D9

Q34233026-C94E75FF-1E15-4BEF-8607-9D09127B597D

Q34233026-CA6A77EE-AD58-4C01-9359-F0A6CE9D094C

Q34233026-FB3AD4C0-B6E4-44CA-B2CC-6D16F7EA4B5E

P2860

Q34233026-09B3AA04-038F-4E79-B8DF-33BE0EA7DB57

Q34233026-32387780-6F04-4AC9-AFFC-7952060C6A5E

Q34233026-3BCE80CE-838A-44A9-9567-0BA6BF24D0B1

Q34233026-3DF79F01-CCCD-46FA-A902-55AA6A94FBFA

Q34233026-40BB614B-85B9-4E2C-964E-C7CA0FD613BB

Q34233026-44B0CCF8-5579-43D6-9A64-81BFCC92895E

Q34233026-4579E4B2-F2CC-45F3-82F6-493D0757E7E9

Q34233026-489CDF32-A55F-4B93-8C17-1D75C7E71F7C

Q34233026-5B0585EA-E54B-410E-814E-E409DB546C7B

Q34233026-7A66BAC1-54F7-4CAA-85C3-F6D355D24452

P304

Q34233026-76C75C44-C7A9-4C62-906F-DAC858F7A39D

P31

Q34233026-4951CE5E-126D-4BDC-92D8-1BE9F26A5BD8

P356

Q34233026-FF6BAEF3-2D8B-4ADA-BFB1-EBB34E4F3FD0

P407

Q34233026-8EDF2789-B929-4441-AFB9-EE7FF980DF3E

P433

Q34233026-952E58FA-5517-4570-A7A2-04AB90F4F823

P478

Q34233026-F492686F-F132-4D20-A471-B9CF69588DCD

P577

Q34233026-C4D16667-7345-4430-BBA4-5F7CDC06354C

P5875

Q34233026-EEA09079-93C1-4F99-B97F-C42958603C17

P698

Q34233026-9EE2B434-0A84-42A0-923D-34E59BBD6581

P921

Q34233026-1A3ED1F1-FE35-44A0-A0C7-AA1FC4F3BCA9

Q34233026-952E6B66-C357-402D-9373-EADBD91B8E73

P932

Q34233026-BEA1F93A-CB92-42F4-95DE-B145C8FFA211

P356

J.JACC.2010.04.016

P1433

Journal of the American College of Cardiology

P1476

Aggregate national experience ...... tes, compliance, and survival.

@en

P2093

Bruce D Lindsay

http://www.w3.org/2001/XMLSchema#string

Edwin Zishiri

http://www.w3.org/2001/XMLSchema#string

Mark J Niebauer

http://www.w3.org/2001/XMLSchema#string

Mina K Chung

http://www.w3.org/2001/XMLSchema#string

Mingyuan Shao

http://www.w3.org/2001/XMLSchema#string

Patrick J Tchou

http://www.w3.org/2001/XMLSchema#string

Steven J Szymkiewicz

http://www.w3.org/2001/XMLSchema#string

P2860

Impact of medication therapy discontinuation on mortality after myocardial infarction

Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction

A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.

Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

A fatal device-device interaction between a wearable automated defibrillator and a unipolar ventricular pacemaker.

Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators.

Analysis of implantable cardioverter defibrillator therapy in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial.

Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS).

Clinical efficacy of a wearable defibrillator in acutely terminating episodes of ventricular fibrillation using biphasic shocks.

Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction.

P304

194-203

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JACC.2010.04.016

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

56

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45149824

http://www.w3.org/2001/XMLSchema#string

P698

20620738

http://www.w3.org/2001/XMLSchema#string

P921

wearable technology

P932

2962668

http://www.w3.org/2001/XMLSchema#string